Mesfin Alemayehu

Mesfin Alemayehu serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through strategic acquisition of scientific and operational services. He manages a diverse portfolio of contracts focused on administrative management consulting, specialized warehousing, and professional technical services that underpin the Institute’s research infrastructure. His work ensures timely and compliant acquisition of mission-critical support functions that enable translational science, data management, and laboratory logistics across NIH’s cancer research ecosystem. His primary contractor relationships center on Quality Biological, Inc., a trusted vendor providing specialized biological materials and associated logistics services critical to preclinical and clinical research workflows. He maintains consistent, long-term partnerships with firms capable of delivering high-integrity scientific support, including storage, distribution, and compliance-driven supply chain services. These relationships reflect a preference for vendors with proven expertise in handling sensitive biological assets under stringent regulatory frameworks. Mesfin demonstrates a strong orientation toward open competition, with the majority of procurements conducted without set-asides. However, he actively incorporates small business participation, with notable awards directed toward Total Small Business Set-Asides and Women-Owned Small Businesses, reflecting a balanced commitment to socioeconomic goals without compromising mission requirements. His contracting patterns align with NIH’s broader efforts to broaden vendor diversity while maintaining scientific rigor. His procurement focus is concentrated in NAICS 541611 for administrative and management consulting services, supporting research operations and program oversight, complemented by NAICS 493190 for specialized warehousing of biological and research materials. He also engages NAICS 541990 for niche scientific and technical services, demonstrating deep familiarity with the unique compliance, safety, and scalability demands of cancer research infrastructure.